Pulmonary Vascular Disease News

In this series, we dive into what rheumatologists should know about pulmonary hypertension, starting an interview with Joseph Parambil, MD, where we learn about the disease, when to suspect and how to work up!

The phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension functional class two or three is ending early due to robust positive evidence found in previous trials, according to a press release.

Among patients with COPD who experienced an exacerbation, the risk for cardiovascular events was highest in the following 2 weeks and stayed elevated more than 1 year after, according to study results.

The FDA approved the phase 2 Explore-OSA trial set to assess the highly selective aldosterone synthase inhibitor, lorundrostat, in adults with obstructive sleep apnea and hypertension, according to a press release.

There has been little research on optimal treatments for pediatric patients with pulmonary arterial hypertension, but the Kids MoD PAH Trial is expected to change this by clearing up if sildenafil plus bosentan or sildenafil only is better.

PHILADELPHIA — Heart failure with preserved ejection fraction may be misdiagnosed in patients with COPD due to symptoms/signs being misinterpreted as COPD, according to a presentation at the 2024 GOLD COPD International Conference.

PHILADELPHIA — With the 2025 GOLD report newly featuring a section dedicated to pulmonary hypertension, it is important that clinicians expand their knowledge of this comorbidity, according to a presentation.

Adults with pulmonary arterial hypertension functional class three or four faced a decreased risk for all-cause mortality or morbidity events with Winrevair vs. placebo, according to phase 3 ZENITH trial topline results.

PHILADELPHIA — To reflect developments in COPD research and care, the 2025 Global Initiative for Chronic Obstructive Lung Disease report features three new sections and several sections that have been updated/revised.